Pathophysiology I: Role of ovarian steroids

The Premenstrual Syndromes: PMS and PMDD

Volumn , Issue , 2007, Pages 83-98

  Rubinow, David R ^a   Schmidt, Peter J ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84908665019     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (210)

1. Reid RL, Yen SSC. Premenstrual syndrome. Am J Obstet Gynecol 1981; 139:85-104.
2. Rubinow DR, Roy-Byrne PP. Premenstrual syndromes: overview from a methodologic perspective. Am J Psychiatry 1984; 141:163-72.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press; 1994.
4. NIMH. NIMH Premenstrual Syndrome Workshop Guidelines. Rockville, MD: National Institute of Mental Health (not published), 1983.
5. Miller WL. Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Clin Perinatol 1998; 25:799-817.
6. Miller WL. Androgen biosynthesis from cholesterol to DHEA. Mol Cell Endocrinol 2002; 198:7-14.
7. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990; 126:1165-72.
8. Naftolin F, Garcia-Segura LM, Keefe D et al. Estrogen effects on the synaptology and neural membranes of the rat hypothalamic arcuate nucleus. Biol Reprod 1990; 42:21-8.
9. Mahendroo MS, Cala KM, Landrum DP et al. Fetal death in mice lacking 5alpha-reductase type 1 caused by estrogen excess. Mol Endocrinol 1997; 11:917-27.
10. Majewska MD, Harrison NL, Schwartz RD et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986; 232:1004-7.
11. A receptor function through distinct sites. Brain Res 1999; 830:72-87.
12. Poletti A, Celotti F, Maggi R et al. Aspects of hormonal steroid metabolism in the nervous system. In: Baulieu E-E, Robel P, Schumacher M, eds. Contemporary Endocrinology: Neurosteroids:A New Regulatory Function in the Nervous System. Totowa, NJ: Humana Press Inc; 1999:97-123.
13. Uht RM, Anderson CM, Webb P et al. Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element. Endocrinology 1997; 138:2900-8.
14. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999; 20:279-307.
15. McEwen BS. Steroid hormones: effect on brain development and function Horm Res 1992; 37(Suppl 3):1-10.
16. Wong M, Moss RL. Long-term and short-term electrophysiological effects of estrogen on the synaptic properties of hippocampal CA1 neurons. J Neurosci 1992; 12:3217-25.
17. Valverde MA, Rojas P, Amigo J et al. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the _ subunit. Science 1999; 285:1929-31.
18. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 1994; 91:8517-21.
19. Ravindra R, Aronstam RS. Progesterone, testosterone and estradiol-17_ inhibit gonadotropin-releasing hormone, stimulation of G protein GTPase activity in plasma membranes from rat anterior pituitary lobe. Acta Endocrinol (Copenh) 1992; 126:345-9.
20. Mermelstein PG, Becker JB, Surmeier DJ. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J Neurosci 1996; 16:595-604.
21. Migliaccio A, Piccolo D, Castoria G et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998; 17:2008-18.
22. Watters JJ, Campbell JS, Cunningham MJ et al. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997; 138:4030-3.
23. Zhang L, Li B, Zhao W et al. Sex-related differences in MAPKs activation in rat astrocytes: effects of estrogen on cell death. Mol Brain Res 2002; 103:1-11.
24. Mani SK. Signaling mechanisms in progesterone-neurotransmitter interactions. Neuroscience 2006; 138:773-81.
25. Auger AP, Meredith JM, Snyder GL et al. Oestradiol increases phosphorylation of a dopamine- and cyclic AMP-regulated phosphoprotein (DARPP-32) in female rat brain. J Neuroendocrinol 2001; 13:761-8.
26. Greengard P. The neurobiology of slow synaptic transmission. Science 2001; 294:1024-30.
27. Brubaker KD, Gay CV. Evidence for plasma membranemediated effects of estrogen. Calcif Tissue Int 1999; 64:459-62.
28. Pilgrim C, Hutchison JB. Developmental regulation of sex differences in the brain: can the role of gonadal steroids be redefined? Neuroscience 1994; 60:843-55.
29. Ciocca DR, Vargas Roig LM. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr Rev 1995; 16:35-62.
30. Behl C, Skutella T, Lezoualc’h F et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997; 51:535-41.
31. Mooradian AD. Antioxidant properties of steroids. J Steroid Biochem Mol Biol 1993; 45:509-11.
32. Singer CA, Rogers KL, Strickland TM et al. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett 1996; 212:13-16.
33. Garcia-Segura LM, Cardona-Gomez P, Naftolin F et al. Estradiol upregulates Bcl-2 expression in adult brain neurons. NeuroReport 1998; 9:593-7.
34. Gouras GK, Xu H, Gross RS et al. Testosterone reduces neuronal secretion of Alzheimer’s beta-amyloid peptides. Proc Natl Acad Sci USA 2000; 97:1202-5.
35. Toran-Allerand CD. Developmental interactions of estrogens with the neurotrophins and their receptors. In: Micevych P, Hammer RP, eds. Neurobiological Effects of Sex Steroid Hormones. Cambridge: Cambridge University Press; 1994:391-411.
36. Zhang L, Ma W, Barker JL et al. Sex differences in expression of serotonin receptors (subtypes 1A and 2A) in rat brain: a possible role of testosterone. Neuroscience 1999; 94:251-9.
37. Juraska JM. The structure of the rat cerebral cortex: effects of gender and the environment. In: Kolb B, Tees RC, eds. The Cerebral Cortex of the Rat. Cambridge, MA: MIT Press; 1990:483-505.
38. Moore CL, Dou H, Juraska JM. Maternal stimulation affects the number of motor neurons in a sexually dimorphic nucleus of the lumbar spinal cord. Brain Res 1992; 572:52-6.
39. Woolley CS, Schwartzkroin PA. Hormonal effects on the brain. Epilepsia 1998; 39:S2-8.
40. McEwen BS, Alves SE, Bulloch K et al. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997; 48(Suppl 7):S8-15.
41. Rachman IM, Unnerstall JR, Pfaff DW et al. Estrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim test. Proc Natl Acad Sci USA 1998; 95:13941-6.
42. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions:implications for affective regulation. Biol Psychiatry 1998; 44:839-50.
43. Pecins-Thompson M, Brown NA, Bethea CL. Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res 1998; 53:120-9.
44. 1A receptors in hippocampal membranes from ovariectomized rats: functional and binding studies. Brain Res 1990; 518:287-91.
45. 1A receptor mRNA in female rat brain. Abstr Soc Neurosci 1997; 23:1501.
46. 2A receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 1995; 54:15-20.
47. Sumner BEH, Fink G. Effects of acute estradiol on 5-hydroxytryptamine and dopamine receptor subtype mRNA expression in female rat brain. Mol Cell Neurosci 1993; 4:83-92.
48. Kendall DA, Stancel GM, Enna SJ. Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding. Science 1981; 211:1183-5.
49. Wissink S, van der Burg B, Katzenellenbogen BS et al. Synergistic activation of the serotonin-1A receptor by nuclear factor-kappa B and estrogen. Mol Endocrinol 2001; 15:543-52.
50. Bethea CL, Mirkes SJ, Su A et al. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology 2002; 27:431-45.
51. Gundlah C, Pecins-Thompson M, Schutzer WE et al. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Mol Brain Res 1999; 63:325-39.
52. Osterlund MK, Halldin C, Hurd YL. Effects of chronic 17_- estradiol treatment on the serotonin 5-HT1A receptor mRNA and binding levels in the rat brain. Synapse 2000; 35:39-44.
53. Krezel W, Dupont S, Krust A et al. Increased anxiety and synaptic plasticity in estrogen receptor beta-deficient mice. Proc Natl Acad Sci USA 2001; 98:12278-82.
54. 1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology 2002; 27:12-24.
55. Hery M, Becquet D, Francois-Bellan AM et al. Stimulatory effects of 5HT1A receptor agonists on luteinizing hormonereleasing hormone release from cultured fetal rat hypothalamic cells: interactions with progesterone. Neuroendocrinology 1995; 61:11-18.
56. 1A agonist, 8-OH-DPAT, on hypothalamic serotonin. Pharmacol Biochem Behav 1995; 51:807-13.
57. Bethea CL, Lu NZ, Gundlah C et al. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002; 23:41-100.
58. 2A receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Mol Brain Res 1999; 73:119-28.
59. Fink G, Sumner BEH. Oestrogen and mental state. Nature 1996; 383:306.
60. McQueen JK, Wilson H, Dow RC et al. Oestradiol-17_ increases serotonin transporter (SERT) binding sites and SERT mRNA expression in discrete regions of female rat brain. J Physiol 1996; 495.P:114P.
61. Su T-P, Schmidt PJ, Danaceau M et al. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997; 82:1220-8.
62. Dinan TG, Barry S, Yatham LN et al. The reproducibility of the prolactin response to buspirone: relationship to the menstrual cycle. Int Clin Psychopharmacol 1990; 5:119-23.
63. Bancroft J, Cook A, Davidson D et al. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med 1991; 21:305-12.
64. O’Keane V, O’Hanlon M, Webb M et al. d-Fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol 1991; 34:289-92.
65. Schmidt PJ, Raju J, Danaceau M et al. The effects of gender and gonadal steroids on the neuroendocrine and temperature response to m-chlorophenylpiperazine in leuprolide-induced hypogonadism in women and men. Neuropsychopharmacology 2002; 27:800-12.
66. Moses EL, Drevets WC, Smith G et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 2000; 48:854-60.
67. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMPdependent protein kinase in rat frontal cortex. J Neurochem 1989; 53:1644-7.
68. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54:597-606.
69. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element-binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16:2365-72.
70. Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994; 14:459-71.
71. Zhou Y, Watters JJ, Dorsa DM. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 1996; 137:2163-6.
72. Sohrabji F, Greene LA, Miranda RC et al. Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol 1994; 25:974-88.
73. Cardona-Gomez P, Perez M, Avila J et al. Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol Cell Neurosci 2004; 25:363-73.
74. Murphy DD, Cole NB, Segal M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95:11412-17.
75. Berman KF, Schmidt PJ, Rubinow DR et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci USA 1997; 94:8836-41.
76. Shaywitz SE, Shaywitz BA, Pugh KR et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999; 281:1197-202.
77. Protopopescu X, Pan H, Altemus M et al. Orbitofrontal cortex activity related to emotional processing changes across the menstrual cycle. Proc Natl Acad Sci USA 2005; 102:16060-5.
78. Goldstein JM, Jerram M, Poldrack R et al. Hormonal cycle modulates arousal circuitry in women using functional magnetic resonance imaging. J Neurosci 2005; 25:9309-16.
79. Redei E, Li L, Halasz I et al. Fast glucocorticoid feedback inhibition of ACTH secretion in the ovariectomized rat: effect of chronic estrogen and progesterone. Neuroendocrinology 1994; 60:113-23.
80. Young EA, Altemus M, Parkinson V et al. Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. Neuropsychopharmacology 2001; 25:881-91.
81. Dayas CV, Xu Y, Buller KM et al. Effects of chronic oestrogen replacement on stress-induced activation of hypothalamic- pituitary-adrenal axis control pathways. J Neuroendocrinol 2000; 12:784-94.
82. Komesaroff PA, Esler M, Clarke IJ et al. Effects of estrogen and estrous cycle on glucocorticoid and catecholamine responses to stress in sheep. Am J Physiol 1998; 275:E671-8.
83. Burgess LH, Handa RJ. Chronic estrogen-induced alterations in adrenocorticotropin and corticosterone secretion, and glucocorticoid receptor-mediated functions in female rats. Endocrinology 1992; 131:1261-9.
84. Carey MP, Deterd CH, de Koning J et al. The influence of ovarian steroids on hypothalamic-pituitary-adrenal regulation in the female rat. J Endocrinol 1995; 144:311-21.
85. Viau V, Meaney MJ. Variations in the hypothalamic-pituitary- adrenal response to stress during the estrous cycle in the rat. Endocrinology 1991; 129:2503-11.
86. Marinari KT, Leschner AI, Doyle MP. Menstrual cycle status and adrenocortical reactivity to psychological stress. Psychoneuroendocrinology 1976; 1:213.
87. Kirschbaum C, Kudielka BM, Gaab J et al. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamic-pituitary-adrenal axis. Psychosom Med 1999; 61:154-62.
88. Collins A, Eneroth P, Landgren B. Psychoneuroendocrine stress responses and mood as related to the menstrual cycle. Psychosom Med 1985; 47:512-27.
89. Ablanalp JM, Livingston L, Rose RM et al. Cortisol and growth hormone responses to psychological stress during the menstrual cycle. Psychosom Med 1977; 39:158-77.
90. Long TD, Ellingrod VL, Kathol RG et al. Lack of menstrual cycle effects on hypothalamic-pituitary-adrenal axis response to insulin-induced hypoglycaemia. Clin Endocrinol (Oxf) 2000; 52:781-7.
91. Galliven EA, Singh A, Michelson D et al. Hormonal and metabolic responses to exercise across time of day and menstrual cycle phase. J Appl Physiol 1997; 83:1822-31.
92. Altemus M, Roca C, Galliven E et al. Increased vasopressin and adrenocorticotropin responses to stress in the midluteal phase of the menstrual cycle. J Clin Endocrinol Metab 2001; 86:2525-30.
93. Roca CA, Schmidt PJ, Altemus M et al. Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 2003; 88:3057-63.
94. Keller-Wood M, Silbiger J, Wood CE. Progesterone attenuates the inhibition of adrenocorticotropin responses by cortisol in nonpregnant ewes. Endocrinology 1988; 123:647-51.
95. Turner BB. Influence of gonadal steroids on brain corticosteriod receptors: a minireview. Neurochem Res 1997; 22:1375-85.
96. Patchev VK, Almeida OFX. Gonadal steroids exert facilitating and ‘buffering’ effects on glucocorticoid-mediated transcriptional regulation of corticotropin-releasing hormone and corticosteroid receptor genes in rat brain. J Neurosci 1996; 16:7077-84.
97. Young EA. The role of gonadal steroids in hypothalamic- pituitary-adrenal axis regulation. Crit Rev Neurobiol 1995; 9:371-81.
98. A receptor alpha-4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998; 392:926-30.
99. Spruce BA, Baylis PH, Burd J et al. Variation in osmoregulation of arginine vasopressin during the human menstrual cycle. Clin Endocrinol 1985; 22:37-42.
100. Wyatt K, Dimmock P, Jones P et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323:776-80.
101. Freeman E, Rickels K, Sondheimer SJ et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA 1990; 264:349-53.
102. Freeman EW, Rickels K, Sondheimer SJ et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274:51-7.
103. Schmidt PJ, Nieman LK, Grover GN et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 1991; 324:1174-9.
104. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double blind comparison with a placebo Acta Psychiatr Scand 1972; 236(Suppl):1-86.
105. Kutner SJ, Brown WL. Types of oral contraceptives, depression and premenstrual symptoms. J Nerv Ment Dis 1972; 155:153-62.
106. Graham CA, Sherwin BB. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J Psychosom Res 1987; 31:45-53.
107. Lewis A, Hoghughi M. An evaluation of depression as a side effect of oral contraceptives. Br J Psychiatry 1969; 115:697-701.
108. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health 1982; 72:1257-64.
109. Marriott A, Faragher EB. An assessment of psychological state associated with the menstrual cycle in users of oral contraception. J Psychosom Res 1986; 30:41-7.
110. Slade P. Premenstrual emotional changes in normal women: fact or fiction? J Psychosom Res 1984; 28:1-7.
111. Sveindottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2001; 79:405-13.
112. Andersch B, Hahn L. Premenstrual complaints. II. Influence of oral contraceptives. Acta Obstet Gynecol Scand 1981; 60:579-83.
113. Glick ID, Bennett SE. Psychiatric complications of progesterone and oral contraceptives. J Clin Psychopharmacol 1981; 1:350-67.
114. Herzberg BN, Johnson AL, Brown S. Depressive symptoms and oral contraceptives. Br Med J 1970; 4:142-5.
115. Kutner SJ, Phillips NR, Hoag EJ. Oral contraceptives, personality, and changes in depression. Contraception 1971; 4:327-36.
116. Moos RH. Psychological aspects of oral contraceptives. Arch Gen Psychiatry 1968; 19:87-94.
117. Freeman EW, Sondheimer S, Weinbaum PJ et al. Evaluating premenstrual symptoms in medical practice. Obstet Gynecol 1985; 65:500-5.
118. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36:257-66.
119. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology 1993; 18:273-81.
120. Freeman EW, Kroll R, Rapkin A et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10:561-9.
121. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:492-501.
122. Watson NR, Savvas M, Studd JWW et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; 334:730-2.
123. Watson NR, Studd JWW, Savvas M et al. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 1990; 4:99-107.
124. Smith RNJ, Studd JWW, Zamblera D et al. A randomised comparison over 8 months of 100 mg and 200 mg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102:475-84.
125. Davis SR. Androgen treatment in women. Med J Aust 1999; 170:545-9.
126. Buckler HM, Misra R, Cantrill JA et al. The use of low dose (100 mg) testosterone implants in severe premenstrual syndrome (PMS). J Endocrinol 1989; 123:34.
127. Sheffield B, Buckler HM, Cantrill JA et al. Double-blind crossover trial of low dose testosterone implants in severe premenstrual syndrome (PMS). J Endocrinol 1989; 121:183.
128. Dhar V, Murphy BEP. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990; 15:489-93.
129. Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril 1991; 56:1066-9.
130. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebocontrolled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20:193-209.
131. Rubinow DR, Hoban MC, Grover GN et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158:5-11.
132. Backstrom T, Sanders D, Leask R et al. Mood, sexuality, hormones, and the menstrual cycle: II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 1983; 45:503-7.
133. Wang M, Seippel L, Purdy RH et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5_-pregnane-3,20-dione and 3_-hydroxy-5_-pregnan-20-one. J Clin Endocrinol Metab 1996; 81:1076-82.
134. Redei E, Freeman EW. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995; 20:259-67.
135. Facchinetti F, Genazzani AD, Martignoni E et al. Neuroendocrine changes in luteal function in patients with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76:1123-7.
136. Backstrom T, Aakvaag A. Plasma prolactin and testosterone during the luteal phase in women with premenstrual tension syndrome. Psychoneuroendocrinology 1981; 6:245-51.
137. Eriksson E, Sundblad C, Lisjo P et al. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 1992; 17:195-204.
138. Bloch M, Schmidt PJ, Su T-P et al. Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls. Biol Psychiatry 1998; 43:897-903.
139. Backstrom T, Wide L, Sodergard R et al. FSH, LH, TeBG-capacity, estrogen and progesterone in women with premenstrual tension during the luteal phase. J Steroid Biochem 1976; 7:473-6.
140. Backstrom T, Smith S, Lothian H et al. Prolonged follicular phase and depressed gonadotropins following hysterectomy and corpus lute-ectomy in women with premenstrual tension syndrome. Clin Endocrinol 1985; 22:723-32.
141. Hammarback S, Damber J-E, Backstrom T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989; 68:125-30.
142. Schechter D, Strasser TJ, Endicott J et al. Role of ovarian steroids in modulating mood in premenstrual syndrome. Abstr Soc Biol Psych 51st Annu Meeting 1996; 646.
143. Halbreich U, Endicott J, Goldstein S et al. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 1986; 74:576-86.
144. A receptor _4 subunit in association with increased anxiety. J Neurosci 1998; 18:5275-84.
145. A receptor function. Pharmacol Biochem Behav 1993; 45:423-8.
146. A receptor. Brain Res 1991; 561:157-61.
147. Wieland S, Lan NC, Mirasedeghi S et al. Anxiolytic activity of the progesterone metabolite 5_-pregnan-3_-ol-20-one. Brain Res 1991; 565:263-8.
148. Purdy RH, Morrow AL, Moore PH Jr et al. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991; 88:4553-7.
149. Ströhle A, Romeo E, Hermann B et al. Concentrations of 3_- reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 1999; 45:274-7.
150. Romeo E, Brancati A, de Lorenzo A et al. Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Clin Neuropharmacol 1996; 19:366-9.
151. Romeo E, Strohle A, Spalletta G et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998; 155:910-13.
152. Uzunova V, Sheline Y, Davis JM et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95:3239-44.
153. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999; 96:13512-17.
154. Sundstrom I, Andersson A, Nyberg S et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67:126-38.
155. Sundstrom I, Nyberg S, Backstrom T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997; 17:370-81.
156. Rapkin AJ, Morgan M, Goldman L et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90:709-14.
157. Schmidt PJ, Purdy RH, Moore PH Jr et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79:1256-60.
158. Sundstrom I, Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 1998; 23:73-88.
159. Rubinow DR, Schmidt PJ. The neuroendocrinology of menstrual cycle mood disorders. Ann NY Acad Sci 1995; 771:648-59.
160. Redei E, Freeman EW. Preliminary evidence for plasma adrenocorticotropin levels as biological correlates of premenstrual symptoms. Acta Endocrinol 1993; 128:536-42.
161. Rosenstein DL, Kalogeras KT, Kalafut M et al. Peripheral measures of arginine vasopressin, atrial natriuretic peptide and adrenocorticotropic hormone in premenstrual syndrome. Psychoneuroendocrinology 1996; 21:347-59.
162. Schmidt PJ, Grover GN, Roy-Byrne PP et al. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76:671-4.
163. Facchinetti F, Martignoni E, Petraglia F et al. Premenstrual fall of plasma _-endorphin in patients with premenstrual syndrome. Fertil Steril 1987; 47:570-3.
164. Chuong CJ, Coulam CB, Kao PC et al. Neuropeptide levels in premenstrual syndrome. Fertil Steril 1985; 44:760-5.
165. Taylor DL, Mathew RJ, Ho BT et al. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12:16-18.
166. Ashby CR Jr, Carr LA, Cook CL et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988; 24:225-33.
167. 6-treatment in premenstrual tension. Neuropsychobiology 1987; 18:83-8.
168. Veeninga AT, Westenberg HGM. Serotonergic function and late luteal phase dysphoric disorder. Psychopharmacology 1992; 108:153-8.
169. Tulenheimo A, Laatikainen T, Salminen K. Plasma _-endorphin immunoreactivity in premenstrual tension. Br J Obstet Gynaecol 1987; 94:26-9.
170. Hamilton JA, Gallant S. Premenstrual symptom changes and plasma _-endorphin/_-lipotropin throughout the menstrual cycle. Psychoneuroendocrinology 1988; 13:505-14.
171. Eriksson E, Alling C, Andersch B et al. Cerebrospinal fluid levels of monoamine metabolites: a preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome. Neuropsychopharmacology 1994; 11:201-13.
172. Parry BL, Gerner RH, Wilkins JN et al. CSF and endocrine studies of premenstrual syndrome. Neuropsychopharmacology 1991; 5:127-37.
173. McNeilly AS, Hagen C. Prolactin, TSH, LH and FSH responses to a combined LHRH/TRH test at different stages of the menstrual cycle. Clin Endocrinol 1974; 3:427-35.
174. Facchinetti F, Genazzani AD, Martignoni E et al. Neuroendocrine correlates of premenstrual syndrome: changes in the pulsatile pattern of plasma LH. Psychoneuroendocrinology 1990; 15:269-77.
175. Reame NE, Marshall JC, Kelch RP. Pulsatile LH secretion in women with premenstrual syndrome (PMS): evidence for normal neuroregulation of the menstrual cycle. Psychoneuroendocrinology 1992; 17:205-13.
176. Lewis LL, Greenblatt EM, Rittenhouse CA et al. Pulsatile release patterns of luteinizing hormone and progesterone in relation to symptom onset in women with premenstrual syndrome. Fertil Steril 1995; 64:288-92.
177. Chuong CJ, Hsi BP. Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertil Steril 1994; 61:1039-44.
178. Facchinetti F, Martignoni E, Sola D et al. Transient failure of central opioid tonus and premenstrual symptoms. J Reprod Med 1988; 33:633-8.
179. Rapkin AJ, Shoupe D, Reading A et al. Decreased central opioid activity in premenstrual syndrome: luteinizing hormone response to naloxone. J Soc Gynecol Invest 1996; 3:93-8.
180. Lacreuse A, Verreault M, Herndon JG. Fluctuations in spatial recognition memory across the menstrual cycle in female rhesus monkeys. Psychoneuroendocrinology 2001; 26:623-39.
181. Dhandapani KM, Mahesh VB, Brann DW. Astrocytes and brain function: implications for reproduction. Exp Biol Medl (Maywood) 2003; 228:253-60.
182. Monteleone P, Luisi S, Tonetti A et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000; 142:269-73.
183. Smith MJ, Schmidt PJ, Su T-P et al. Gonadotropin-releasing hormone-stimulated gonadotropin levels in women with premenstrual dysphoria. Gynecol Endocrinol 2004; 19:335-43.
184. Casson P, Hahn PM, VanVugt DA et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162:99-105.
185. Muse KN, Cetel NS, Futterman LA et al. The premenstrual syndrome:effects of ‘medical ovariectomy’. N Engl J Med 1984; 311:1345-9.
186. Sarno AP, Miller EJ Jr, Lundblad EG. Premenstrual syndrome:beneficial effects of periodic, low-dose danazol. Obstet Gynecol 1987; 70:33-6.
187. Bancroft J, Boyle H, Warner P et al. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol 1987; 27:171-82.
188. West CP, Hillier H. Ovarian suppression with the gonadotrophinreleasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 1994; 9:1058-63.
189. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 71:252A-F.
190. Mezrow G, Shoupe D, Spicer D et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62:932-7.
191. Muse K. Gonadotropin-releasing hormone agonist-suppressed premenstrual syndrome (PMS): PMS symptom induction by estrogen, progestin, or both. Abst Soc Gynecol Invest 1989; 118.
192. Girdler SS, Straneva PA, Light KC et al. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001; 49:788-97.
193. Facchinetti F, Fioroni L, Martignoni E et al. Changes of opioid modulation of the hypothalamo-pituitary-adrenal axis in patients with severe premenstrual syndrome. Psychosom Med 1994; 56:418-22.
194. Rabin DS, Schmidt PJ, Campbell G et al. Hypothalamic- pituitary-adrenal function in patients with the premenstrual syndrome. J Clin Endocrinol Metab 1990; 71:1158-62.
195. Parry BL, Javeed S, Laughlin GA et al. Cortisol circadian rhythms during the menstrual cycle and with sleep deprivation in premenstrual dysphoric disorder and normal control subjects. Biol Psychiatry 2000; 48:920-31.
196. Odber J, Cawood EHH, Bancroft J. Salivary cortisol in women with and without premenstrual mood changes. J Psychosom Res 1998; 45:557-68.
197. Parry BL, Hauger R, Lin E et al. Neuroendocrine effects of light therapy in late luteal phase dysphoric disorder. Biol Psychiatry 1994; 36:356-64.
198. Steiner M, Haskett RF, Carroll BJ. Circadian hormone secretory profiles in women with severe premenstrual tension syndrome. Br J Obstet Gynaecol 1984; 91:466-71.
199. Eriksson E, Humble M. Serotonin in psychiatric pathophysiology:a review of data from experimental and clinical research. In: Pohl R, Gershon S, eds. The Biological Basis of Psychiatric Treatment. Basel: Karger; 1990:66-119.
200. Linnoila M, Virkkunen M, George T et al. Impulse control disorders. Int Clin Psychopharmacol 1993; 8:53-6.
201. Wurtman JJ. Carbohydrate craving: relationships between carbohydrate intake and disorders of mood. Drugs 1990; 39:49-52.
202. Keck PE Jr, Hudson JI, Dorsey CM et al. Effect of fluoxetine on sleep: letter to the editor. Biol Psychiatry 1991; 29:618-25.
203. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55:406-13.
204. Schmidt PJ, Rosenfeld D, Muller KL et al. A case of autoimmune thyroiditis presenting as menstrual related mood disorder. J Clin Psychiatry 1990; 51:434-6.
205. Bancroft J. The premenstrual syndrome - a reappraisal of the concept and the evidence. Psychol Med 1993; Suppl 24:1-47.
206. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of premenstrual syndrome. Psychopharmacol Bull 1990; 26:331-5.
207. DeJong R, Rubinow DR, Roy-Byrne PP et al. Premenstrual mood disorder and psychiatric illness. Am J Psychiatry 1985; 142:1359-61.
208. Paddison PL, Gise LH, Lebovits A et al. Sexual abuse and premenstrual syndrome: comparison between a lower and higher socioeconomic group. Psychosomatics 1990; 31:265-72.
209. Dreher J, Schmidt PJ, Kohn P, et al. Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci USA 2007; 104:2465-70.
210. Ochedalski T, Subburaju S, Wynn PC et al. Interaction between oestrogen and oxytocin on hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2007; 19:189-97.